{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:48:35Z","timestamp":1794383315536,"version":"4.9.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Neoadjuvant therapy (NAT) is increasingly used to treat patients with initially unresectable intrahepatic cholangiocarcinoma (iCCA). A histopathologic grading system for residual tumors that can predict patient survival is lacking in the literature. This retrospective study enrolled 151 iCCA patients who received NAT. The percentage of residual viable tumor (%RVT) extent was calculated by RVT surface area\/total tumor bed area \u00d7100 and scored in 5% increments. Kaplan-Meier and Cox regression analyses were used to investigate its correlations with recurrence-free survival (RFS) and overall survival (OS). Tumor regression grading by the College of American Pathologists (CAP) and MD Anderson (MDA) methodologies were also validated. A 10% RVT-based tumor regression score (TRS) showed a significant correlation with both OS and RFS. TRS and major pathologic response (mPR) were therefore defined as follows: TRS 1\/mPR, tumor with 0 to 10% RVT; TRS 2, more than 10% RVT. Patients graded as TRS 1\/mPR had superior OS (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.006) and RFS (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) compared with those with TRS 2 in univariate analysis. In a multivariate analysis including ypTNM stages, lymphovascular invasion, and perineural invasion, TRS 1\/mPR was also found to be an independent prognostic factor for both OS (hazard ratio [HR]: 0.226; 95% CI: 0.053-0.966, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.045) and RFS (HR: 0.474; 95% CI: 0.231-0.974, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.042). As for the CAP and MDA grading methodologies, they were found to correlate with RFS (CAP: <jats:italic toggle=\"yes\">P<\/jats:italic>=0.002; MDA: <jats:italic toggle=\"yes\">P<\/jats:italic>=0.001), but not with OS (CAP: <jats:italic toggle=\"yes\">P<\/jats:italic>=0.181; MDA: <jats:italic toggle=\"yes\">P<\/jats:italic>=0.09). Our study revealed that a TRS of \u226410% RVT significantly correlates with longer OS and RFS and can be suggested as an mPR in iCCA. This indicator is easily applicable, prognostically relevant, and could be further validated in future prospective clinical trials.<\/jats:p>","DOI":"10.1097\/pas.0000000000002359","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:00:52Z","timestamp":1742371252000},"page":"578-587","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Histopathologic Grading of Residual Tumor Predicts Survival of Intrahepatic Cholangiocarcinoma Patients Treated With Neoadjuvant Therapy"],"prefix":"10.1097","volume":"49","author":[{"given":"Gaohua","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Liver Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Singapore General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongkui","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Xin","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony Kiat Hon","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Singapore General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Chew","sequence":"additional","affiliation":[{"name":"Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Liver Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Liver Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Liver Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Liver Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Kandang Kerbau Women\u2019s and Children\u2019s Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"R1-20250514","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"R2-20250514","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R3-20250514","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R4-20250514","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/hep.32007","article-title":"Comparison of clinical features and outcomes between intrahepatic cholangiocarcinoma and hepatocellular carcinoma in the United States","volume":"74","author":"Lee","year":"2021","journal-title":"Hepatology"},{"key":"R5-20250514","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3322\/caac.21759","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R6-20250514","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg"},{"key":"R7-20250514","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"R8-20250514","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jso.23762","article-title":"Outcomes in biliary malignancy","volume":"110","author":"Groot Koerkamp","year":"2014","journal-title":"J Surg Oncol"},{"key":"R9-20250514","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1245\/s10434-012-2312-8","article-title":"Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study","volume":"20","author":"Kato","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R10-20250514","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/bjs.10641","article-title":"Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"105","author":"Le Roy","year":"2018","journal-title":"Br J Surg"},{"key":"R11-20250514","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol"},{"key":"R12-20250514","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S1470-2045(21)00383-1","article-title":"Revisiting neoadjuvant therapy in non-small-cell lung cancer","volume":"22","author":"Saw","year":"2021","journal-title":"Lancet Oncol"},{"key":"R13-20250514","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jamaoncol.2023.3323","article-title":"Neoadjuvant immune checkpoint inhibitor therapy for localized deficient mismatch repair colorectal cancer: a review","volume":"9","author":"Emiloju","year":"2023","journal-title":"JAMA Oncol"},{"key":"R14-20250514","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/15384047.2020.1834792","article-title":"Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases","volume":"22","author":"Zhao","year":"2021","journal-title":"Cancer Biol Ther"},{"key":"R15-20250514","doi-asserted-by":"crossref","first-page":"744571","DOI":"10.3389\/fimmu.2021.744571","article-title":"Successful treatment of advanced intrahepatic cholangiocarcinoma with a high tumor mutational burden and PD-L1 expression by PD-1 blockade combined with tyrosine kinase inhibitors: a case report","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"R16-20250514","doi-asserted-by":"crossref","first-page":"1079342","DOI":"10.3389\/fimmu.2022.1079342","article-title":"Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: a case report and literature review","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"R17-20250514","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R18-20250514","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"R19-20250514","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"R20-20250514","doi-asserted-by":"crossref","first-page":"472","DOI":"10.21037\/hbsn-22-527","article-title":"Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review","volume":"13","author":"Wang","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R21-20250514","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"R22-20250514","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"R23-20250514","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R24-20250514","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi","year":"2018","journal-title":"J Clin Oncol"},{"key":"R25-20250514","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.3390\/cancers14133213","article-title":"Could we predict the response of immune checkpoint inhibitor treatment in hepatocellular carcinoma?","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R26-20250514","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"key":"R28-20250514","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1016\/j.annonc.2020.08.116","article-title":"1243P Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis","volume":"31","author":"Waser","year":"2020","journal-title":"Ann Oncol"},{"key":"R29-20250514","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/PAS.0000000000001853","article-title":"Pathologic examination of pancreatic specimens resected for treated pancreatic ductal adenocarcinoma: recommendations from the Pancreatobiliary Pathology Society","volume":"46","author":"Wang","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R30-20250514","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2559.2005.02176.x","article-title":"Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer","volume":"47","author":"Ryan","year":"2005","journal-title":"Histopathology"},{"key":"R31-20250514","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00428-024-03937-y","article-title":"Tumor budding in pre-neoadjuvant biopsy and post-neoadjuvant resection specimens is associated with poor prognosis in intrahepatic cholangiocarcinoma-a cohort study of 147 cases by modified ITBCC criteria","volume":"485","author":"Wu","year":"2024","journal-title":"Virchows Arch"},{"key":"R32-20250514","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1159\/000509424","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition)","volume":"9","author":"Zhou","year":"2020","journal-title":"Liver Cancer"},{"key":"R33-20250514","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R34-20250514","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/PAS.0000000000001601","article-title":"A critical assessment of postneoadjuvant therapy pancreatic cancer regression grading schemes with a proposal for a novel approach","volume":"45","author":"Chou","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R35-20250514","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1078-0432.CCR-19-2379","article-title":"Pan-tumor pathologic scoring of response to PD-(L)1 blockade","volume":"26","author":"Stein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R36-20250514","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000738","article-title":"Validation of a proposed tumor regression grading scheme for pancreatic ductal adenocarcinoma after neoadjuvant therapy as a prognostic indicator for survival","volume":"40","author":"Lee","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R37-20250514","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMp1205737","article-title":"Pathological complete response and accelerated drug approval in early breast cancer","volume":"366","author":"Prowell","year":"2012","journal-title":"N Engl J Med"},{"key":"R38-20250514","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"R39-20250514","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","article-title":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group","volume":"28","author":"Provenzano","year":"2015","journal-title":"Mod Pathol"},{"key":"R40-20250514","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"R41-20250514","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2019.09.081","article-title":"Calculating the tumor nuclei content for comprehensive cancer panel testing","volume":"15","author":"Mikubo","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R42-20250514","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/his.13891","article-title":"Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study","volume":"75","author":"Dufraing","year":"2019","journal-title":"Histopathology"},{"key":"R43-20250514","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00428-016-2042-6","article-title":"Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment","volume":"470","author":"Lhermitte","year":"2017","journal-title":"Virchows Arch"},{"key":"R44-20250514","first-page":"100420","article-title":"Major pathologic response and prognostic score predict survival in patients with lung cancer receiving neoadjuvant chemotherapy","volume":"3","author":"Pataer","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"R45-20250514","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/SLA.0b013e318262a591","article-title":"Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery","volume":"256","author":"Becker","year":"2012","journal-title":"Ann Surg"},{"key":"R46-20250514","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1245\/s10434-013-3410-y","article-title":"A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapy","volume":"21","author":"Langer","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R47-20250514","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/bjc.2015.354","article-title":"The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence","volume":"113","author":"Lagarde","year":"2015","journal-title":"Br J Cancer"},{"key":"R48-20250514","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/IGC.0000000000001306","article-title":"The importance of lymphovascular invasion in uterine adenosarcomas: analysis of clinical, prognostic, and treatment outcomes","volume":"28","author":"Nathenson","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R49-20250514","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","article-title":"Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment","volume":"29","author":"de Jong","year":"2011","journal-title":"J Clin Oncol"},{"key":"R50-20250514","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41379-021-00871-1","article-title":"Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer","volume":"34","author":"Liu","year":"2021","journal-title":"Mod Pathol"},{"key":"R51-20250514","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","article-title":"Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma","volume":"40","author":"Hayashi","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R52-20250514","doi-asserted-by":"crossref","first-page":"154126","DOI":"10.1016\/j.prp.2022.154126","article-title":"Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: Results from a German tertiary center","volume":"238","author":"Kinzler","year":"2022","journal-title":"Pathol Res Pract"},{"key":"R53-20250514","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","article-title":"Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features","volume":"27","author":"Liau","year":"2014","journal-title":"Mod Pathol"},{"key":"R54-20250514","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/PAS.0000000000001118","article-title":"Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns","volume":"42","author":"Sigel","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R55-20250514","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.humpath.2020.12.005","article-title":"An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping","volume":"109","author":"Akita","year":"2021","journal-title":"Hum Pathol"},{"key":"R56-20250514","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.21873\/anticanres.13325","article-title":"Comparison of the clinicopathological features in small bile duct and bile ductular type intrahepatic cholangiocarcinoma","volume":"39","author":"Yamada","year":"2019","journal-title":"Anticancer Res"},{"key":"R57-20250514","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.14218\/JCTH.2023.00118","article-title":"Expert consensus on pathological diagnosis of intrahepatic cholangiocarcinoma (2022 version)","volume":"11","author":"Wang","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"R58-20250514","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/his.15162","article-title":"Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma","volume":"84","author":"Kinzler","year":"2024","journal-title":"Histopathology"},{"key":"R59-20250514","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00432-024-05888-y","article-title":"Small duct and large duct type intrahepatic cholangiocarcinoma reveal distinct patterns of immune signatures","volume":"150","author":"Bernatz","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"R60-20250514","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1097\/pas.0000000000002597","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000}},{"DOI":"10.1097\/pas.0000000000002597","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000}}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T14:00:18Z","timestamp":1747231218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002359"}},"subtitle":["Major Pathologic Response and Its Clinical Significance"],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002359","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]}}}